ELI Lilly And Company
Indianapolis, IN
- UEI
- UHHVNTY54K68
- CAGE
- 75602
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- WMGGU7AM5JF6
-
- SAM.gov registration date
- Physical address
- 893 S Delaware St, Indianapolis, IN 46225, USA
- Website
- lilly.com
- Founded
- 1876
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $286,375 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $286,375 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Private lands agreement | Fish and Wildlife Service | $5,000 | |
| Nysgxrc:a large scale center for the PSI | National Institutes of Health | $18,893,617 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Pfizer Inc. | New York, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Astrazeneca Pharmaceuticals LP | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
| Prasco, LLC | Mason, OH | 325412 Pharmaceutical Preparation Manufacturing |
| Bristol-Myers Squibb Company | Lawrence Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Merck Sharp & Dohme LLC | Rahway, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
ELI Lilly And Company, a for-profit pharmaceutical manufacturer headquartered in Indianapolis, Indiana, supplies drugs, biologicals, radiopharmaceuticals, and medical devices to federal agencies exclusively as a prime contractor (100% of awards), competing full-and-open with no set-aside designations across a portfolio of 713 awards valued at $23.32 billion in combined potential value.
ELI Lilly's federal footprint centers on two distinct capability streams. The dominant stream is bulk pharmaceutical supply through Defense Logistics Agency (DLA) indefinite delivery contracts and basic ordering agreements — 353 of the vendor's 516 awards tracked in the source originated from DLA, with five parent vehicles (Indefinite Delivery Contract DLA12089D0352 with 55 task orders, IDC DLA12092D0380 with 47 task orders, and three basic ordering agreements carrying 33, 36, and 24 task orders respectively) accounting for the highest task-order volume. The second stream is specialized monoclonal antibody treatments and radiopharmaceuticals supplied directly to the Department of Veterans Affairs and the Department of the Army under firm fixed price delivery orders and definitive contracts. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 accounts for the largest single concentration by dollar value — five awards with $15.57 billion combined potential value, anchored by a $2.1 billion definitive contract awarded February 10, 2022, for BEBTELOVIMAB monoclonal antibody COVID-19 treatment, and a $1.29 billion delivery order from November 1, 2021, for 614,000 doses of combination monoclonal antibody. The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense holds six awards valued at $7.75 billion, all supporting the federal COVID-19 response with combination monoclonal antibody and BEBTELOVIMAB products. Recent work includes delivery orders from Veterans Integrated Service Networks for AMYVID radiopharmaceutical products (F-18 AMYVID beta amyloid imaging, florbetapir F-18 injection solution) placed under ELI Lilly's September 29, 2025, GSA Federal Supply Schedule Pharmaceuticals and Drugs (FSS-61-IB) contract carrying an $8 billion ceiling through September 28, 2030.
Activity is light in recent years — two awards in both 2025 and 2026 — reflecting contract completion and reorder dynamics rather than new vehicle wins. Top PSC codes track pharmaceutical (568 awards under "Drugs And Biologicals") and medical device supply (92 awards under "Medical And Surgical Instruments, Equipment, And Supplies"); top NAICS includes Pharmaceutical Preparation Manufacturing and Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers. ELI Lilly holds a subsidiary, Dermira, Inc., also a for-profit organization, though the source does not detail Dermira's role in the federal footprint. Combined dollars obligated across all awards total $4.78 billion (20% of combined potential value), indicating ongoing invoicing against contracts with substantial remaining ceiling. The vendor operates places of performance at Knoxville, Tennessee and Indianapolis, Indiana.
Quick answers
Is ELI Lilly And Company registered in SAM.gov?
ELI Lilly And Company's SAM.gov registration expired on October 16, 2026.
Which contract vehicles does ELI Lilly And Company hold?
ELI Lilly And Company holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has ELI Lilly And Company received in federal contracts?
Federal contracts obligated $286,375 to ELI Lilly And Company in fiscal years 2023 through 2027.
What is ELI Lilly And Company's most recent federal award?
ELI Lilly And Company's most recent federal contract award is Amyvid_beta amyloid imaging (36C25226F0408), from Veterans Integrated Service Network 12 (VHA), on August 17, 2026.
On GovTribe
See ELI Lilly And Company's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors